Paclitaxel-loaded TPGS enriched self-emulsifying carrier causes apoptosis by modulating survivin expression and inhibits tumour growth in syngeneic mammary tumours

Jaya Gopal Meher, Shivani Dixit, Darshad Khan Pathan, Yuvraj Singh, Hardik Chandasana, Vivek K. Pawar, Mani Sharma, Rabi Sankar Bhatta, Rituraj Konwar, Prashant Kesharwani,

Artificial Cells Nanomedicine and Biotechnology · 2018 · 33 citations · 22 references

DOIFull text

Open access

Concepts

Abstract

M cell cycle arrest, apoptosis, mitochondrial membrane potential disruption and ROS production was exhibited by PTX-SEDDS in comparison to Taxol. Up-regulation of Bax, p21, cleaved-caspase 3, -caspase 9 and down-regulation of Bcl2 and survivin suggested apoptosis via intrinsic pathways. Pharmacokinetic study showed approximately 4-folds higher oral bioavailability of PTX-SEDDS than Taxol. Significant reduction in tumour volume and weight was observed in syngeneic mammary tumour in SD rats. Tumour histopathology and TUNEL assay showed apoptosis in tumour tissue. PTX-SEDDS caused low lung metastasis, and was safe and stable. Conclusively, PTX-SEDDS could be suitable option for oral delivery of PTX.

References

22